Research and Development of a Second-Generation Process for Oseltamivir Phosphate, Prodrug for a Neuraminidase Inhibitor

2004 ◽  
Vol 8 (1) ◽  
pp. 86-91 ◽  
Author(s):  
Peter J. Harrington ◽  
Jack D. Brown ◽  
Tommaso Foderaro ◽  
Robert C. Hughes
Keyword(s):  
Research And Development ◽  
Second Generation ◽  
Neuraminidase Inhibitor ◽  
Generation Process ◽  
Oseltamivir Phosphate

Research and Development of a Second-Generation Process for Bosentan, an Endothelin Receptor Antagonist

2002 ◽  
Vol 6 (2) ◽  
pp. 120-124 ◽  
Author(s):  
Peter J. Harrington ◽  
Hiralal N. Khatri ◽  
Brad S. DeHoff ◽  
Martin R. Guinn ◽  
Mark A. Boehler ◽  
...  
Keyword(s):  
Research And Development ◽  
Receptor Antagonist ◽  
Second Generation ◽  
Endothelin Receptor Antagonist ◽  
Generation Process ◽  
Endothelin Receptor

The Synthetic Development of the Antiinfluenza Neuraminidase Inhibitor Oseltamivir Phosphate (Tamiflu): A Challenge for Synthesis & Process Research

ChemInform ◽  
2005 ◽  
Vol 36 (30) ◽  
Author(s):  
Stefan Abrecht ◽  
Peter Harrington ◽  
Hans Iding ◽  
Martin Karpf ◽  
Rene Trussardi ◽  
...  
Keyword(s):  
Neuraminidase Inhibitor ◽  
Process Research ◽  
Synthesis Process ◽  
Oseltamivir Phosphate

scholarly journals Collaboration and Composition: Issues for a Second Generation Process Language

1999 ◽  
pp. 75-90 ◽  
Author(s):  
B. C. Warboys ◽  
D. Balasubramaniam ◽  
R. M. Greenwood ◽  
G. N. C. Kirby ◽  
K. Mayes ◽  
...  
Keyword(s):  
Second Generation ◽  
Generation Process

The Remote Manipulator System Second Generation Schemes

1980 ◽  
Vol 24 (1) ◽  
pp. 209-213 ◽  
Author(s):  
J.R. McCullough
Keyword(s):  
Research And Development ◽  
Second Generation ◽  
Technology Development ◽  
Space Shuttle ◽  
Handling System

The Shuttle Remote Manipulator System is the payload handling system of the Space Shuttle Orbiter and will be used to deploy and retrieve satellites on-orbit. This paper gives an overview of future on-orbit manipulator tasks and discusses potential second generation RMS schemes. The paper concludes by identifying areas of research and development that will be required to ensure the appropriate level of technology development.

scholarly journals Anti-Influenza Neuraminidase Inhibitor Oseltamivir Phosphate Induces Canine Mammary Cancer Cell Aggressiveness

PLoS ONE ◽  
2015 ◽  
Vol 10 (4) ◽  
pp. e0121590 ◽  
Author(s):  
Joana T. de Oliveira ◽  
Ana L. Santos ◽  
Catarina Gomes ◽  
Rita Barros ◽  
Cláudia Ribeiro ◽  
...  
Keyword(s):  
Cancer Cell ◽  
Mammary Cancer ◽  
Neuraminidase Inhibitor ◽  
Mammary Cancer Cell ◽  
Canine Mammary Cancer ◽  
Oseltamivir Phosphate

ANTECEDENTS OF SUCCESS IN A RESEARCH AND DEVELOPMENT CONSORTIUM

2019 ◽  
pp. 2150001
Author(s):  
JORGE DOMINGUEZ-BLANCO ◽  
IGNACIO CASTRO-ABANCÉNS ◽  
GABRIEL CEPEDA-CARRION
Keyword(s):  
Research And Development ◽  
Latent Variables ◽  
Second Generation ◽  
Positive Influence ◽  
Sem Algorithm ◽  
Determinant Factors ◽  
Generation Technique ◽  
The Relationship

This study explores and examines the relationship between the success of Research and Development (R&D) consortia and the factors that determine this success. Most studies of R&D consortium success are based on a set of observable variables as antecedents of this success. In our study, we recognise the complexity of the problem and use latent variables as a set of weighted observable variables, rather than classical variables. Empirical insights are provided by applying a second-generation technique, namely the PLS-SEM algorithm, to analyse the data gathered from R&D consortia in Spain. The results demonstrate the existence of constructs (partner attributes, alliance attributes, environment attributes and leadership) that encompass the determinant factors for success, and also show that the attributes of the partners and the characteristics of the project alliances exert a positive influence on the success of the joint R&D project.

Research and Development on High-Temperature Gasification Technology of Woody Biomass for Fuel Cell Power Generation Process

2004 ◽  
Vol 30 (4) ◽  
pp. 385-390 ◽  
Author(s):  
Guilin PIAO ◽  
Agung Sri HENDARSA ◽  
Yasuo ADACHI ◽  
Yoshinori ITAYA ◽  
Michihiko HAMAI ◽  
...  
Keyword(s):  
Power Generation ◽  
High Temperature ◽  
Fuel Cell ◽  
Research And Development ◽  
Woody Biomass ◽  
Generation Process ◽  
Gasification Technology

scholarly journals Effect of oseltamivir phosphate versus placebo on platelet recovery and plasma leakage in adults with dengue and thrombocytopenia; a phase 2, multicenter, double-blind, randomized trial

2022 ◽  
Vol 16 (1) ◽  
pp. e0010051
Author(s):  
Rahajeng N. Tunjungputri ◽  
Silvita Fitri Riswari ◽  
Setyo G. Pramudo ◽  
Lydia Kuntjoro ◽  
Bachti Alisjahbana ◽  
...  
Keyword(s):  
Platelet Count ◽  
Randomized Trial ◽  
Neuraminidase Inhibitor ◽  
Phase 2 ◽  
Double Blind ◽  
Platelet Recovery ◽  
Duration Of Illness ◽  
Plasma Leakage ◽  
Discharge From Hospital ◽  
Oseltamivir Phosphate

Background Thrombocytopenia, bleeding and plasma leakage are major complications of dengue. Activation of endogenous sialidases with desialylation of platelets and endothelial cells may underlie these complications. We aimed to assess the effects of the neuraminidase inhibitor oseltamivir on platelet recovery and plasma leakage in dengue. Methods We performed a phase 2, double-blind, multicenter, randomized trial in adult dengue patients with thrombocytopenia (<70,000/μl) and a duration of illness ≤ 6 days. Oseltamivir phosphate 75mg BID or placebo were given for a maximum of five days. Primary outcomes were the time to platelet recovery (≥ 100,000/μl) or discharge from hospital and the course of measures of plasma leakage. Results A total of 70 patients were enrolled; the primary outcome could be assessed in 64 patients (31 oseltamivir; 33 placebo). Time to platelet count ≥100,000/μl (n = 55) or discharge (n = 9) were similar in the oseltamivir and placebo group (3.0 days [95% confidence interval, 2.7 to 3.3] vs. 2.9 days [2.5 to 3.3], P = 0.055). The kinetics of platelet count and parameters of plasma leakage (gall bladder thickness, hematocrit, plasma albumin, syndecan-1) were also similar between the groups. Discussion In this trial, adjunctive therapy with oseltamivir phosphate had no effect on platelet recovery or plasma leakage parameters. Trial registration ISRCTN35227717.

Sign in / Sign up

Export Citation Format

Share Document